Dexcom Inc
Research Dexcom Inc (DXCM) on Bullrun: valuation model: 9.2% overvalued, market cap USD 31.74B, P/E 33.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDXCM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal9.2% overvalued
- Market capUSD 31.74B
- P/E33.2
- Financial periodQ2 2026
- RevenueUSD 1.31B
- Net incomeUSD 249.10M
- Free cash flowUSD 184.50M
- Gross margin63.4%
Valuation Snapshot
Bullrun's latest valuation model marks Dexcom Inc as 9.2% overvalued; latest market cap is USD 31.74B; P/E is 33.2.
Peer valuation comparison
Latest P/E is 33.2x versus a Healthcare sector median of 24.61x (34.9% above).
Latest P/E is 33.2x versus a United States median of 23.85x (39.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.66B | USD 836.30M | USD 1.08B | 60.1% | 2.09 | USD 917.70M | USD 1.39B | USD 2.75B |
| FY2024 | USD 4.03B | USD 576.20M | USD 630.70M | 60.5% | 1.42 | USD 606.10M | USD 2.59B | USD 2.10B |
| FY2023 | USD 3.62B | USD 541.50M | USD 511.90M | 63.2% | 1.3 | USD 566.30M | USD 2.59B | USD 2.07B |
| FY2022 | USD 2.91B | USD 341.20M | USD 304.70M | 64.7% | 0.82 | USD 642.30M | USD 2.15B | USD 2.13B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 31.74B | 33.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 25.54B | 31.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.38B | 54.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 47.36B | 137.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 43.74B | 191.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 52.09B | 253.3 | n/a | n/a |
About Dexcom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions;
ETFs that hold Dexcom Inc
Dexcom Inc is one of the ten largest holdings of 9 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares US Medical Devices UCITS ETF USD (Acc) | 3.38% | 0.25% |
| VanEck Genomics and Healthcare Innovators UCITS ETF | 6.42% | 0.35% |
| VanEck Medical Robotics and Bionic Engineering UCITS ETF | 7.74% | 0.55% |
| Global X Telemedicine & Digital Health ETF A | 4.94% | 0.68% |
| Global X InternetofThings | 5.92% | 0.60% |
| Global X S&P 500 Annual Tail Hedge UCITS ETF | 5.23% | 0.50% |
| Global X Telemedicine & Digital Health ETF D | 4.53% | 0.68% |
| Fidelity Digital Health UCITS ETF USD Acc | 4.93% | 0.50% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Dexcom Inc overvalued or undervalued?
Bullrun's valuation model currently marks Dexcom Inc as 9.2% overvalued.
What is Dexcom Inc's market cap?
Dexcom Inc's market capitalization is USD 31.74B.
What is Dexcom Inc's P/E ratio?
Dexcom Inc's price-to-earnings (P/E) ratio is 33.2.
What does Dexcom Inc do?
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.